Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir

BACKGROUND/AIMS: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB). However, the long-term outcomes of LAM+ADV and 1-mg entecavir (ETV) rescue therapies have still been limited. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ze, EunYoung, Baek, Eun Kyung, Lee, Jong Jin, Chung, Han Wook, Ahn, Dae Geon, Cho, Hwan Jun, Kwon, Jae Cheol, Kim, Hyung Joon, Lee, HyunWoong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197175/
https://www.ncbi.nlm.nih.gov/pubmed/25320730
http://dx.doi.org/10.3350/cmh.2014.20.3.267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197175/
https://www.ncbi.nlm.nih.gov/pubmed/25320730
http://dx.doi.org/10.3350/cmh.2014.20.3.267

Ejemplares similares